T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies - Wikidata - awgldk - TriplyDB

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

http://www.wikidata.org/entity/Q34923799

about

Adoptive T-Cell Immunotherapy Engineered T cells for cancer treatment Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors Expression of the immune regulation antigen CD70 in osteosarcoma.CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.Immunotherapy targets in pediatric cancer.Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies Immunotherapeutic strategies to target prognostic and predictive markers of cancer.Design and development of therapies using chimeric antigen receptor-expressing T cells CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?Antibody-modified T cells: CARs take the front seat for hematologic malignancies.Targeting costimulatory molecules to improve antitumor immunity.Adoptive immunotherapy for cancer.Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.Genetically modified T cells to target glioblastoma.Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.Adoptive Cell Therapy in Multiple Myeloma.Novel Immunotherapies for Multiple Myeloma.The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma.Engineered T cells: the promise and challenges of cancer immunotherapy.Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.Tumor-targeting domains for chimeric antigen receptor T cells.Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27.Engineering Chimeric Antigen Receptors.Treatment of advanced leukemia in mice with mRNA engineered T cells.T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC.The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation.CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells.A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.CAR T cell therapy for multiple myeloma: where are we now and where are we headed?Chimeric antigen receptor T-cell therapies for multiple myeloma.CD70, a novel target of CAR T-cell therapy for gliomas.Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy.Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.

P2860

Q26782845-E0719B67-993D-4890-BFBB-4B76E4AD7737 Q33578792-A4A3073C-8E7A-43E1-9F9E-5119B79054A1 Q34256494-A966182D-83FB-4F36-B7B6-99DE2779189F Q34309388-65501167-5898-4C10-BEC1-52B16ED3E750 Q35194116-72AA86DE-6110-4EAD-8010-2540F94C99E2 Q35691210-B531FACD-F760-4A86-BDFA-EA94A2208E5B Q35971029-380B8F3D-7E1D-49EA-810C-9C1D91C8E6A5 Q36366557-E0CB47B7-05B5-4BDF-B332-6582F6E71566 Q36662079-4FC51C61-C308-406F-AE30-BA4E42EC5507 Q36965071-4280B52E-B7DC-4595-B6B0-B73E5785F7D9 Q37126006-E5AE8A12-A254-4EED-A8F1-1D37CFBA6286 Q37418289-A5CC279F-F5BB-4F4F-B188-0D0F4265C189 Q37587956-5C0BB195-BD71-40D1-B1C7-BF424F6C57AA Q37723469-EA8E1E17-2C34-42F7-89C8-1EF310E7E912 Q38002404-C61AC777-FA42-4B23-AB0B-BE66B96E7942 Q38170496-3C17B5F2-59A8-4B4F-B8B9-0980C1A6B929 Q38170500-04B46193-ABD6-406A-A220-931653014465 Q38178690-D3F13DD8-E5B5-4333-A5BE-3B79B920ECAD Q38435415-C14C6AF3-CE5D-4F7D-B70F-ACEBDF7F14FF Q38633640-4542F412-4A15-4F87-AB96-C42A67DF6AC7 Q38635138-D6C52012-8091-427F-8EB2-57643A781F16 Q38640444-67A80AA0-15FA-48C6-9943-9322A300E847 Q38764944-35ADD793-5C20-4E62-BC0C-C0D64E6160E9 Q38828829-34785F89-E483-46EA-A66D-CB2304A77B0F Q38839878-3F3FDC69-2752-46FA-AF5D-F0C2DBAB8CA6 Q39045535-B4451CDE-E3F8-447E-A864-D27BDB2F5F6B Q39233648-282D475A-2EDA-4121-8C4A-C1C8A94886D4 Q39276909-0E17152E-7745-4D0E-A3B9-76C4736BF5ED Q39784230-C3EBC9FC-2723-420A-A534-0A0AD70A604B Q40064011-73BABCDB-EA7E-4F06-B62D-2C56965ED7FE Q40095245-6279116E-E29D-49D5-A7C8-A8BD0432C6E6 Q40406380-677B4547-28A6-48F3-9B46-4FBF8B2553EA Q42427577-03E62721-21C9-40ED-A0B2-27A3571D92A7 Q45870963-E08E54C9-8E0C-4FF0-8602-5F52461D52D2 Q47549907-77D92E1A-E7EA-4FDB-B23F-0BC731F0147A Q47565827-070560BB-2DCE-40BF-9AC4-91DFC0DB8AEB Q47776210-1B3A219D-B48F-42DC-92B0-2511E80779D8 Q48223703-95AFEB51-BE5F-4690-9D17-8337C680FBC5 Q50027358-03B070CA-2813-4D9A-8BB0-3CF8B333FE79 Q50037939-4D277527-0A4F-4F98-8A49-F9288CBB0F35

P2860

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

http://www.wikidata.org/entity/Q34923799

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

@ast

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

@en

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

@nl

type

label

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

@ast

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

@en

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

@nl

prefLabel

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

@ast

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

@en

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

@nl

P1433

Q34923799-0AC82E13-15CD-4DC6-AA03-D319AEC3171C

P1476

Q34923799-C560C216-E7EE-45A9-BB13-F3B8D993A3E1

P2093

Q34923799-13E17C84-17E1-4354-AD76-A66B61EE600C

Q34923799-3A482E19-98D4-42CE-AB08-682DA2425911

Q34923799-3BAF5896-B836-4C2B-902D-AE6A01FC1972

Q34923799-56ECD8A7-252E-412E-BF14-2A1272DCB3E8

Q34923799-6BE1A17C-EB0E-4C88-8761-ED56180D9395

Q34923799-7EB1C71A-2A91-4416-AD15-BA51349A0328

Q34923799-B921BF13-B93E-42EC-B1EA-F9AFDA5A1963

Q34923799-D63EAA56-8CF5-4EA6-89E9-902DBA979D1A

Q34923799-E2308711-B99B-43C5-B414-5D3CB29450AF

Q34923799-ED14B9FE-CAAC-47F5-94A5-8DECF42F5C20

P2860

Q34923799-032D77D5-F34D-4711-AB96-617F75772EE8

Q34923799-072A2CDE-AC09-4945-8E10-CDA091D8413C

Q34923799-087657B1-48BA-4DEF-9F55-22A2CA547B0E

Q34923799-11261124-E38F-4F81-A691-53836723FC6D

Q34923799-12951C8C-7CA5-4702-919A-B945D8D2F778

Q34923799-17544B91-AEFB-47BD-9324-80C78AD27946

Q34923799-19F9D18A-44DD-4F12-8F62-1DEEAD58C900

Q34923799-1F23A520-20B7-41F7-91E0-FBAA9D19A37F

Q34923799-22ED1C9D-B9FC-4D53-BE7B-8C361F5A1600

Q34923799-2310D369-4D22-46C8-A006-503275D677B1

P304

Q34923799-D986601E-AF67-44F3-BA81-EC67AA9429B5

P31

Q34923799-9A456BBF-E44C-41C9-94DF-41D973CE2808

P356

Q34923799-204D6FA1-CF84-4ADA-994D-5841605F68E3

P407

Q34923799-9F41244C-99AB-4174-8E4B-9FAA03241442

P433

Q34923799-F093281C-B2A2-4F5E-BBCB-E7C129608D04

P478

Q34923799-2C162FE0-C51D-4FFB-AFF3-229B1645330F

P577

Q34923799-92A1F018-393A-456A-A12D-E5CF235D869D

P5875

Q34923799-D6B0BFF0-FA74-46C0-B66E-4B1AD03EA02D

P698

Q34923799-6D891D13-87B7-4414-9A86-BBC76CE66723

P921

Q34923799-4FE37704-5BBF-4B5F-B26D-A4AE326EE3D2

P932

Q34923799-FAF92AF1-CB60-4F47-B5FC-BEDFE075D761

P356

BLOOD-2010-04-278218

P1433

P1476

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

@en

P2093

Barbara Savoldo

http://www.w3.org/2001/XMLSchema#string

David M Spencer

http://www.w3.org/2001/XMLSchema#string

Donald R Shaffer

http://www.w3.org/2001/XMLSchema#string

Gianpietro Dotti

http://www.w3.org/2001/XMLSchema#string

Hao Liu

http://www.w3.org/2001/XMLSchema#string

Kevin K H Chow

http://www.w3.org/2001/XMLSchema#string

Meng-Fen Wu

http://www.w3.org/2001/XMLSchema#string

Shannon Kenney

http://www.w3.org/2001/XMLSchema#string

Stephen Gottschalk

http://www.w3.org/2001/XMLSchema#string

Sunitha Kakarla

http://www.w3.org/2001/XMLSchema#string

P2860

The cloning of CD70 and its identification as the ligand for CD27

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells

NF-kappaB activation in CD27 signaling: involvement of TNF receptor-associated factors in its signaling and identification of functional region of CD27

Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas

Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production.

Highly enhanced expression of CD70 on human T-lymphotropic virus type 1-carrying T-cell lines and adult T-cell leukemia cells.

Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies

Aberrant expression and reverse signalling of CD70 on malignant B cells.

P304

4304-4314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-04-278218

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49820177

http://www.w3.org/2001/XMLSchema#string

P698

21304103

http://www.w3.org/2001/XMLSchema#string

P921

P932

3087480

http://www.w3.org/2001/XMLSchema#string